

This document is an English-translated version of an attachment of a notification for Revision of PRECAUTIONS issued by the Ministry of Health, Labour and Welfare.

This English version is intended to be a reference material to provide convenience for users.

In the event of inconsistency between the Japanese original and this English translation, the former shall prevail.

Revision of PRECAUTIONS

Triazolam

March 17, 2026

Therapeutic category

Hypnotics and sedatives, antianxiotics

Non-proprietary name

Triazolam

Safety measure

PRECAUTIONS should be revised.

This document is an English-translated version of an attachment of a notification for Revision of PRECAUTIONS issued by the Ministry of Health, Labour and Welfare.
 This English version is intended to be a reference material to provide convenience for users.
 In the event of inconsistency between the Japanese original and this English translation, the former shall prevail.

Revised language is underlined.

Current			Revision		
2. CONTRAINDICATIONS (This drug is contraindicated to the following patients.) Patients receiving the following drugs: Itraconazole, posaconazole, fluconazole, fosfluconazole, voriconazole, miconazole, HIV protease inhibitors (atazanavir sulfate, darunavir ethanolate, fosamprenavir calcium hydrate, ritonavir, lopinavir/ritonavir), nirmatrelvir/ritonavir, ensitrelvir fumaric acid, preparations containing cobicistat, efavirenz			2. CONTRAINDICATIONS (This drug is contraindicated to the following patients.) Patients receiving the following drugs: Itraconazole, posaconazole, fluconazole, fosfluconazole, voriconazole, miconazole, HIV protease inhibitors (atazanavir sulfate, darunavir ethanolate, fosamprenavir calcium hydrate, ritonavir, lopinavir/ritonavir), nirmatrelvir/ritonavir, ensitrelvir fumaric acid, preparations containing cobicistat, efavirenz, <u>ceritinib</u>		
10. INTERACTIONS 10.1 Contraindications for Co-administration (Do not co-administer with the following.)			10. INTERACTIONS 10.1 Contraindications for Co-administration (Do not co-administer with the following.)		
Drugs	Signs, symptoms, and treatment	Mechanism/risk factors	Drugs	Signs, symptoms, and treatment	Mechanism/risk factors
(N/A)	(N/A)	(N/A)	<u>Ceritinib</u>	<u>The blood concentration of this drug may rise. The effects may be enhanced, and the duration of effects may be prolonged.</u>	<u>Since this drug and the drugs listed on the left-hand side are metabolized by the same enzyme (CYP3A4), the metabolism of this drug is inhibited.</u>

N/A: Not Applicable. No corresponding language is included in the current PRECAUTIONS.